Consumer guide for cancer drugs may be an effective decision-making aide
the ONA take:
The American Society of Clinical Oncology task force of cancer physicians, patient advocates, and insurance and pharmaceutical company representatives has devised a “Value Framework” for available cancer drugs. The decision aide is intended to help physicians and patients weigh the pluses and minuses of treatment options for a wide range of cancers.
The Value Framework uses a rating system to assess a drug’s effectiveness in extending life for cancer patients and the number and severity of side effects. Although cost is not a direct factor in a drug’s net health benefit score, it is a significant factor in patient decisions on treatment and was crucial to the development of the decision aide.
Factors that make up a drug’s net health benefit index is how many more months of progression-free survival clinical trial participants had compared with those on standard treatments, number and severity of toxicities or unwanted side effects. The decision aide would also provide the treatment’s monthly cost.
One drawback of the Value Framework is that much of its initial information is based on established medical practices and research that predates current precision medicine practices. As the genetics of cancers advance, many drugs are found to offer benefit to a subset of patients, rather than to a wide group.
The task force is optimistic that the Value Framework will be able to keep up with the advances being made in precision medicine. They anticipate that the value of certain treatment regimens may be refined over time.
The American Society of Clinical Oncology task force has devised a “Value Framework” for available cancer drugs.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|